Posted on 20 May 2015
Reliable cognitive measures for patients with Alzheimer's disease are essential when testing potential new drug interventions. The high attrition rate in Alzheimer’s disease clinical trials highlights the need for more sensitive analytical tools to be used throughout the drug development process.
Posted on 18 May 2015
Posted on 12 May 2015
In March 2015, the Food and Drug Administration approved the first biosimilar in the U.S., it is now more important than ever to ensure the cognitive safety and tolerability of drugs is tested throughout clinical development.
Posted on 5 May 2015
The digital healthcare arena is one of the fastest changing sectors. Director of Healthcare Innovation, Jenny Barnett presented around the theme of ‘Future applications’ and discussing the use of Cognitive Assessment Software for Assessing Central Nervous System Disorders at The Institution of Engineering and Technology and the Royal Society of Medicine's joint one day seminar on The Future of Medicine and the Role of the Doctor in 2025.